Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in iranian women

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 4113-4117

  Izadi, Pantea ^a,b   Noruzinia, Mehrdad ^b   Fereidooni, Foruzandeh ^c   Nateghi, Mohammad Reza ^d  

^a Medical School   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Breast cancer subtypes; Estrogen receptor alpha; Iranian patients; Promoter methylation

Indexed keywords

EID: 84873651134     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.4113     Document Type: Article

References (40)

1. Badve S, Nakshatri H (2009). Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol, 62, 6-12.
2. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
3. Chen XS, Ma CD, Wu JY, et al (2010). Molecular subtype approximated by quantitative estrogne receptor, progestron receptor and Her2 can predict the prognosis of breast cancer. Tumori, 96, 103-10.
4. Chuthapisith S, Permsapaya W, Warnnissorn M, et al (2012). Breast Cancer Subtypes Identified by the ER, PR and HER-2 Status in Thai Women. Asian Pac J Cancer Prev, 3, 459-62.
5. Dunnwald, LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characterstics, and prognosis:a prospective cohort of breast cancer patients. Breast Cancer Res, 9, 6.
6. Fallahazad V, Kamalian N, Gransar A (2004). The prevalence of estrogen and progestron receptors in breast cancer in Shariati general hospital of Tehran. J Tehran Med Faculty, 62, 745-8.
7. Gwon AM (2008). Current issues in ER and Her2 testing by IHC in breast cancer. Modern pathology, 21, 8-15.
8. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ (2004). Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev, 5, 24-7.
9. Hayashi S, Niwa T, Yamaguchi Y (2009). Estrogen signaling pathway and its imaging in human breast cancer. Cancer Sci, 100, 1773-8.
10. Herman JG, Graff, JR, Myhanen S, Nelkin BD, Baylin SB (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 93, 9821-6.
11. Hill VK, Ricketts C, Bieche I, et al (2011). Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorogenicity. Cancer Res, 15, 2988-99.
12. Hines LM, Risendal B, Byers T, et al (2011). Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women. J Womens Health (Larchmt), 20, 1543-50.
13. Ihemelandu CU, Leffall LD, Jr Dewitty RL, et al (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res, 143, 109-18.
14. Issa JP, Ottaviano YL, Celano P, et al (1994). Methylation of the estrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet, 7, 536-40.
15. Iwase H, Omoto Y, Iwata H, et al (1999). DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br J Cancer, 80, 1982-6.
16. Killian JK, Bike S, Davis S, et al (2011). A methyl-deviator epigenotype of estrogen receptor positive breast carcinoma is associated with malignant biology. Am J Pathol, 179, 55-65.
17. Kolahdoozan, S, Sadjadi A, Radmard AR, Khademi H (2010). Five common cancers in Iran. Arch Iran Med, 13, 143-6.
18. Kos M, Reid G, Denger S, Gannon F (2001). Minireview: genomic organization of the human ERalpha gene promoter region. Mol Endocrinol, 15, 2057-63.
19. Lapidus RG, Nass SJ, Butash KA, et al (1998). Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res, 58, 2515-9.
20. Lee JS, Fackler MJ, Lee JH, et al (2010). Basal like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther, 9, 1017-24.
21. Li S, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett, 237, 272-80.
22. Mirza S, Sharma G, Prasad CP, et al (2007). Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci, 81, 280-7.
23. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
24. Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in Iran:An epidemilogical review. Breast J, 13, 383-91.
25. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009). Breast cancer subtypes based on ER/PR and Her2 expression:comparison of clinicopathological features and survival. Clinical Med Res, 7, 4-13.
26. Parrella P, Poeta ML, Gallo AP, et al (2004). Nonrandom distribution of aberrant promoter methylation of cancerrelated genes in sporadic breast tumors. Clin Cancer Res, 10, 5349-54.
27. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumors. Nature, 406, 747-52.
28. Polyak K (2007). Breast cancer: origins and evolution. J Clin Invest, 117, 3155-63.
29. Post WS, Goldschmidt-Clermont PJ, Wihide CC, et al (1999). Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res, 43, 985-91.
30. Ramezani F, Salami S, Omrani MD, Maleki D (2012). CpG Island Methylation Profile of Estrogen Receptor Alpha in Iranian Female with Triple Negative or Non-triple Negative Breast Cancer: New Marker of Poor prognosis. APJCP, 13, 451-7.
31. Ronneberg JA, Fleischer T, Solvang HK, et al (2011). Methylation profiling with a panel of cancer related genes: association with estrogen receptor, Tp53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol, 5, 61-76.
32. Sandhu R, Parker JS, Jones DW, Livasy CA, Coleman WB. (2010). Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy. Lab Med, 41, 364-72.
33. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
34. Travis RC, Key TJ (2003). Oestrogen exposure and breast cancer risk. Breast Cancer Res, 5, 239-47.
35. Vahdaninia M, Montazeri A (2004). Survival rate of breast cancer. Asia Pac J Cancer Prev, 5, 223-5.
36. Vallejos CS, Gomez HL, Cruz WR, et al (2010). Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer, 10, 294-300.
37. Veeck J, Esteller M (2010). Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia, 15, 5-17.
38. Voduc KD, Cheang MCU, Tyldesely S, et al (2010). Breast cancer subtypes and risk of local and regional relapse. J Clin Oncol, 28, 1684-91.
39. Wei M, Xu J, Dignam J, et al (2008). Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat, 111, 113-20.
40. Zhao L, Wang L, Jin F, et al (2009). Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer. Breast Cancer Res Treat, 117, 253-9.